Paper Details

  1. Home
  2. Paper Details

HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.

Author: Al AshgarHamad, Al FaddaAbdulrahman, Al JedaiAhmed, Al KahtaniKhalid, Al QuaizMohammed, Al SohaibaniFahad, Al ThawadiSahar, KhanMohammed Q, PeedikayilMusthafa C, ThoralssonEinar

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The study investigated whether adding PEGylated interferon (PEG IFN) to tenofovir treatment for chronic hepatitis B virus (HBV) infection can improve HBsAg clearance, the ideal endpoint for HBV treatment.
Paper Details　
Original Abstract of the Article :
The ideal end point of treatment for chronic hepatitis B virus (HBV) infection is sustained off-therapy hepatitis B surface antigen (HBsAg) loss with or even without seroconversion to anti-HBs. We investigated the role of adding PEGylated interferon (PEG IFN) to ongoing tenofovir treatment in chroni...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470379/

データ提供：米国国立医学図書館（NLM）

Pegylated Interferon Alfa-2a as an Add-On Therapy for Chronic Hepatitis B

Chronic hepatitis B virus (HBV) infection presents a significant challenge in the field of hepatology. While antiviral therapies, such as tenofovir, can suppress viral replication, the ultimate goal is to achieve sustained off-therapy HBsAg clearance. This study, exploring the realm of antiviral therapy, investigates the role of adding pegylated interferon (PEG IFN) to ongoing tenofovir treatment for achieving HBsAg clearance in patients with chronic HBV.

PEG IFN's Impact on HBsAg Clearance

The study, a randomized controlled trial, explores the effectiveness of adding PEG IFN to ongoing tenofovir treatment for chronic HBV infection. While the research provides valuable insights into the potential of PEG IFN as an add-on therapy, it highlights the complexity of managing chronic HBV infection and the need for further research to optimize treatment strategies and improve outcomes for patients.

The Importance of Continued Research in Hepatitis B Treatment

This research underscores the importance of continued research in the field of HBV treatment, focusing on achieving sustained HBsAg clearance and ultimately improving the lives of patients living with this chronic infection.

Dr.Camel's Conclusion

Imagine a camel crossing a vast desert, searching for a hidden oasis. Just as the camel perseveres, seeking a source of life-giving water, researchers continue to explore new avenues to combat chronic HBV infection. This research, while offering a glimpse of potential, reminds us that the journey towards finding lasting solutions for HBV is ongoing and requires unwavering dedication to achieving a healthier future for patients.

Date :
  1. Date Completed 2018-04-02
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28611343

DOI: Digital Object Identifier

PMC5470379

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.